A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Janaki Ramachandran of the AIADMK became the first woman to hold the position of the state's chief minister. J. Jayalalithaa of the AIADMK became the youngest Chief Minister of Tamil Nadu at the age of 43 in 1991, and had the second longest tenure, holding the office for more than fourteen years across multiple terms. There have been four instances of President's rule in Tamil Nadu, most recently in 1991. C. Joseph Vijay of the Tamilaga Vettri Kazhagam is the incumbent Chief Minister since 10 May 2026.
==== Embryology ==== Cephalopod eggs span a large range of sizes, from 1 to 30 mm in diameter. The fertilised ovum initially divides to produce a disc of germinal cells at one pole, with the yolk remaining at the opposite pole. The germinal disc grows to envelop and eventually absorb the yolk, forming the embryo. The tentacles and arms first appear at the hind part of the body, where the foot would be in other molluscs, and only later migrate towards the head. The funnel of cephalopods develops on the top of their head, whereas the mouth develops on the opposite surface. The early embryological stages are reminiscent of ancestral gastropods and extant Monoplacophora. The shells develop from the ectoderm as an organic framework which is subsequently mineralized. In Sepia, which has an internal shell, the ectoderm forms an invagination whose pore is sealed off before this organic framework is deposited.
There are also small-molecule medications that provide temporary relief. Before Onpattro was released, the treatment options for hATTR were limited. After the approval of Onpattro, the FDA awarded Alnylam with the Breakthrough Therapy Designation, which is given to drugs that are intended to treat a serious condition and are a substantial improvement over any available therapy. It was also awarded Orphan Drug Designations given to those treatments that are intended to safely treat conditions affecting fewer than 200,000 people. Along with Onpattro, another RNA interference therapeutic drug, patisiran, has also been developed, which has the property of inhibiting hepatic synthesis of transthyretin. As a result, target messenger RNA (mRNA) is cleaved by small interfering RNAs coupled to the RNA-induced silencing complex. Patisiran, an RNAi therapeutic drug, uses this process to decrease the production of mutant and wild-type transthyretin by cleaving the 3' untranslated region of transthyretin mRNA. In 2019, the FDA approved the second RNAi therapy, Givlaari (givosiran), used to treat acute hepatic porphyria (AHP). The disease is caused by the accumulation of toxic porphobilinogen (PBG) molecules, which are formed during the production of heme. These molecules accumulate in different organs, and this can lead to the symptoms or attacks of AHP. Givlaari is an siRNA drug that downregulates the expression of aminolevulinic acid synthase 1 (ALAS1), a liver enzyme involved in an early step in heme production.
== Etymology and pronunciation == The word epithelium uses the Greek roots ἐπί (epi), "on" or "upon", and θηλή (thēlē), "nipple". Epithelium is so called because the name was originally used to describe the translucent covering of small "nipples" of tissue on the lip. The word has both mass and count senses; the plural form is epithelia.
Sources: en.wikipedia.org
The transport of the MHC class I molecules through the secretory pathway involves several posttranslational modifications of the MHC molecule. Some of the posttranslational modifications occur in the ER and involve change to the N-glycan regions of the protein, followed by extensive changes to the N-glycans in the golgi apparatus. The N-glycans mature fully before they reach the cell surface.
Chloromorphide (α-chloromorphide) is an opiate analog that is a derivative of morphine, where the 6-hydroxy group has been replaced by chlorine. Developed in 1933 in Germany, it has approximately ten times the potency of morphine. It has similar effects to morphine, such as sedation, analgesia, and respiratory depression. Chloromorphide does not appear specifically in the Controlled Substances Act 1970 in the United States, but is presumably Schedule II controlled substance as a form of morphine or an analogue of morphine or morphinan. When halogenated morphides and codides are used for research or industrial uses, they are often synthesised on-site. Chloromorphide is one of a series of opioids known as morphides and codides, which are important precursors and intermediates in the synthesis of semi-synthetic opioid analgesic drugs, especially those with additions, substitutions, or other modifications at the 7, 8, and/or 14 positions on the morphine carbon skeleton. Semisynthetics with changes at other positions can also be made from these compounds. The codeine analog of chloromorphide is α-chlorocodide (alpha-chlorcodide), an intermediate in one method of desomorphine synthesis which uses codeine as precursor. During the 1930s, the entire series of alpha- and beta-halogenated codides, morphides, dihydromorphides, and dihydrocodides were produced and described, and α-bromomorphide and α-iodomorphide are sometimes currently used in research and manufacturing.
Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period of myocardial cells. Because of its Class III antiarrhythmic activity, there should not be concomitant administration of Class Ia and Class III agents. Ibutilide is marketed as Corvert by Pfizer. Administration resulted in successful heart rhythm control in 31–44% of patients within 90 minutes, with sustained polymorphic ventricular tachycardia in 0.9–2.5% of patients. It appears to show better results in atrial flutter as compared to atrial fibrillation.
Several studies have suggested that breast milk can pass antibodies to the infant for as long as the child continues to nurse. The antibodies may be in the mother's system as a result of being ill, or they may be acquired by drinking milk from a mother who has recently been vaccinated for a particular disease. One small study done on nursing mothers who had received the COVID-19 vaccine found that breastmilk continued to contain antibodies for as long as 80 days after receiving the vaccine.
=== Polymers === In polymer chemistry, MALDI can be used to determine the molar mass distribution. Polymers with polydispersity greater than 1.2 are difficult to characterize with MALDI due to the signal intensity discrimination against higher mass oligomers. A good matrix for polymers is dithranol or AgTFA. The sample must first be mixed with dithranol and the AgTFA added afterwards; otherwise the sample will precipitate out of solution.
Sources: en.wikipedia.org
=== Serotonin precursor === Tryptophan affects brain serotonin synthesis when given orally in a purified form and is used to modify serotonin levels for research. Low brain serotonin level is induced by administration of tryptophan-poor protein in a technique called acute tryptophan depletion. Studies using this method have evaluated the effect of serotonin on mood and social behavior, finding that serotonin reduces aggression and increases agreeableness.
It looked terrible coming at the fag end of the recession, when the government had a tiny majority, and just after the fiasco of Black Wednesday and the scandal of David Mellor's resignation. Heseltine was attacked by Marcus Fox, Jim Pawsey, Nicholas Winterton, Bill Cash, Rhodes Boyson and his former supporter David Evans who called openly for him to be sacked. The High Court found that Heseltine and British Coal had acted "unlawfully and irrationally". Faced with likely defeat in the House of Commons, Heseltine was forced to agree to a moratorium, during which time he attempted, largely unsuccessfully, to seek new markets for British coal and to obtain government subsidies for pits. The band Chumbawamba released the critical song "Mr Heseltine meets the public" that portrayed Heseltine as an out-of-touch figure; the same group had once dedicated a song to the village of Fitzwilliam, West Yorkshire, which was reduced to a ghost village by the closure of the local coal pits. In February 1993, Heseltine announced that unlike the Dutch and Belgian governments, Britain would not be contributing to any bailout of Anglo-Dutch DAF Trucks (which in the event went bankrupt in June). By early 1993 Heseltine's fortunes were at a low ebb, with his future as a minister being called into question. A review into the pit closures appeared in March 1993. By this time, public anger had cooled. By the start of 1997, British Coal had been reduced to 28 pits.
American biochemist of Ukrainian-Jewish origin, who discovered metabolic regulation by feedback inhibition. Henry Berkeley Franks (Hal) Dixon (1928–2008). British enzymologist at the University of Cambridge. Malcolm Dixon FRS (1899–1985). British biochemist at the University of Cambridge. Research on enzyme structure, kinetics, and properties. His book (with Edwin C. Webb) Enzymes was very influential.
The large numbers of people involved in demography are often difficult to comprehend. A useful visualisation tool is the audience capacity of large sports stadiums (often about 100,000). Often the capacity of the largest stadium in a region serves as a unit for a large number of people. For example, Uruguay's Estadio Centenario is often used in Uruguay, while in parts of the United States, Michigan Stadium is used in this manner. In Australia, the capacity of the Melbourne Cricket Ground (about 100,000) is often cited in this manner. Hence the Melbourne Cricket Ground serves as both a measure of people and a unit of volume.
Cholesterol is the principal sterol of all animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Cholesterol is biosynthesized by all animal cells and is an essential structural and signaling component of animal cell membranes. In vertebrates, hepatic cells typically produce the greatest amounts of it. In the brain, astrocytes produce cholesterol and transport it to neurons. It is absent among prokaryotes (bacteria and archaea), although there are some exceptions, such as Mycoplasma, which require cholesterol for growth. Cholesterol also serves as a precursor for the biosynthesis of steroid hormones, bile acid, and vitamin D. Elevated levels of cholesterol in the blood, especially when bound to low-density lipoprotein (LDL, often referred to as "bad cholesterol"), may increase the risk of cardiovascular disease. François Poulletier de la Salle first identified cholesterol in solid form in gallstones in 1769. In 1815, chemist Michel Eugène Chevreul named the compound "cholesterine".
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.